Your fact-checks will appear here
Ivermectin has shown antiproliferative, proapoptotic, and resistance-reversing effects in various cancer cell lines and animal models.
Preclinical evidence places and its downstream Akt/mTOR axis as the single most consistently implicated route for —especially in where ivermectin promotes ubiquitin-mediated degradation of PAK1, reduc...
both reduce PAK1-driven signaling in preclinical cancer models, but they do so by different molecular routes and with different translational implications: ivermectin promotes proteasome-mediated degr...
shows repeated anticancer activity in cell culture and some animal models, but translating those effects to humans faces clear and : the concentrations that kill tumor cells in vitro are often in the ...
Preclinical research ties ’s anticancer activity to at least three interlocking mechanisms: suppression of Wnt/β‑catenin signaling, inhibition of the PAK1/Akt/mTOR axis with induction of autophagy/apo...
Preclinical mouse studies of ivermectin report effective antitumor activity across a wide dose range—commonly 0.5–10 mg/kg and in some reviews up to 40 mg/kg—with many experiments using ~3–10 mg/kg to...